Comparison of Twin-block and Dynamax appliances for the treatment of Class II malocclusion in adolescents: A randomized controlled trial COMMENT

被引:10
作者
Thiruvenkatachari, Badri
Sandler, Jonathan
Murray, Alison
Walsh, Tanya
O'Brien, Kevin
机构
[1] Department of Orthodontics, School of Dentistry, University of Manchester, Manchester
[2] Chesterfield Royal Hospital NHS Trust, Chesterfield
[3] Consultant Orthodontist, Derbyshire Royal Infirmary, Derbyshire
[4] Department of Statistics, School of Dentistry, University of Manchester, Manchester
[5] School of Dentistry, University of Manchester, Manchester, M15 6FH, Higher Cambridge St
关键词
D O I
10.1016/j.ajodo.2010.04.002
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Introduction: The aim of this study was to compare the effectiveness of Twin-block and Dynamax appliances for the treatment of Class II Division 1 malocclusion. Methods: This was a randomized controlled trial involving 32 boys and 32 girls aged 10 to 14 years with Class II Division 1 malocclusion. They were randomly allocated to either the Dynamax appliance group or the Twin-block appliance group. Treatment was provided by 4 clinicians at 2 centers. Records were taken at the start and the end of the functional phase and after all treatment. In addition, incisal overjet, the number of appliance breakages, and adverse events or side effects of the treatment were recorded at each patient visit. Results: The data monitoring committee in an interim analysis at 18 months after the start of the trial found significantly greater overjet reduction in the Twin-block group than in the Dynamax group and more breakages and adverse events with the Dynamax appliance. As a result, treatment with the Dynamax appliance was terminated, and those patients completed treatment with the Twin-block or a fixed appliance. Regression analysis showed a statistically significant difference in the performance over time between the Twin-block and Dynamax appliances in terms of reduction in overjet, with the Twin-block appliance performing significantly better than the Dynamax. The incidence of adverse events was greater in the Dynamax group (82%) than in the Twin-block group (16%), with a statistically significant difference (P<0.001) between the 2 groups. Conclusions: The Twin-block appliance was more effective than the Dynamax appliance when overjet was evaluated and the Dynamax appliance patients reported greater incidence of adverse events with their appliance than those who were treated with the Twin-block appliance. (Am J Orthod Dentofacial Orthop 2010; 138: 144.e1-144.e9)
引用
收藏
页码:144 / 145
页数:2
相关论文
共 21 条
[1]  
Aladdin H, 2000, SCAND J IMMUNOL, V51, P520
[2]   Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials [J].
Anderson, Garnet L. ;
Kooperberg, Charles ;
Geller, Nancy ;
Rossouw, Jacques E. ;
Pettinger, Mary ;
Prentice, Ross L. .
CLINICAL TRIALS, 2007, 4 (03) :207-217
[3]  
Bass Neville M, 2003, J Clin Orthod, V37, P268
[4]   Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects [J].
Blanckenberg, DH ;
Wood, R ;
Horban, A ;
Beniowski, M ;
Boron-Kaczmarska, A ;
Trocha, H ;
Halota, W ;
Schmidt, RE ;
Fatkenheuer, G ;
Jessen, H ;
Lange, JMA .
AIDS, 2004, 18 (04) :631-640
[5]   A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients:: Excess mortality associated with high-dose clarithromycin [J].
Cohn, DL ;
Fisher, EJ ;
Peng, GT ;
Hodges, JS ;
Chesnut, J ;
Child, CC ;
Franchino, B ;
Gibert, CL ;
El-Sadr, W ;
Hafner, R ;
Korvick, J ;
Ropka, M ;
Heifets, L ;
Clotfelter, J ;
Munroe, D ;
Horsburgh, CR .
CLINICAL INFECTIOUS DISEASES, 1999, 29 (01) :125-133
[6]   Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) [J].
Cohn, JN ;
Pfeffer, MA ;
Rouleau, J ;
Sharpe, N ;
Swedberg, K ;
Straub, M ;
Wiltse, C ;
Wright, TJ .
EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (05) :659-667
[7]  
Dickersin K, 1997, AIDS EDUC PREV, V9, P15
[8]   A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection [J].
Feinberg, JE ;
Hurwitz, S ;
Cooper, D ;
Sattler, FR ;
MacGregor, RR ;
Powderly, W ;
Holland, GN ;
Griffiths, PD ;
Pollard, RB ;
Youle, M ;
Gill, MJ ;
Holland, FJ ;
Power, ME ;
Owens, S ;
Coakley, D ;
Fry, J ;
Jacobson, MA .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (01) :48-56
[9]   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].
Goss, PE ;
Ingle, JN ;
Martino, S ;
Robert, NJ ;
Muss, HB ;
Piccart, MJ ;
Castiglione, M ;
Tu, D ;
Shepherd, LE ;
Pritchard, KI ;
Livingston, RB ;
Davidson, NE ;
Norton, L ;
Perez, EA ;
Abrams, JS ;
Therasse, P ;
Palmer, MJ ;
Pater, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802
[10]   Maternal toxicity with continuous nevirapine in pregnancy - Results from PACTG 1022 [J].
Hitti, J ;
Frenkel, LM ;
Stek, AM ;
Nachman, SA ;
Baker, D ;
Gonzalez-Garcia, A ;
Provisor, A ;
Thorpe, EM ;
Paul, ME ;
Foca, M ;
Gandia, J ;
Huang, S ;
Wei, LJ ;
Stevens, LM ;
Watts, DH ;
McNamara, J .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (03) :772-776